临床与病理杂志2025，Vol.45Issue(2)：149-156,8.DOI:10.11817/j.issn.2095-6959.2025.240505
血清HE4联合其他肿瘤标志物在肺癌中的临床应用
Clinical application of serum HE4 combined with other tumor markers in lung cancer
摘要
Abstract
Objective:Lung cancer is one of the most common malignancies worldwide.Common tumor markers such as carcinoembryonic antigen(CEA),neuron-specific enolase(NSE),cytokeratin 19 fragment(CYFRA21-1),squamous cell carcinoma antigen(SCCA),and progastrin-releasing peptide(ProGRP)are widely used for differential diagnosis,prognosis,and treatment monitoring of lung cancer.However,their value in early diagnosis remains limited.of lung cancer.Human epididymis protein 4(HE4)has been detected at elevated levels in the serum and tissues of lung cancer patients and is considered a novel tumor marker for this disease.This study aims to explore the expression levels and clinical significance of serum HE4 and 5 other tumor markers in lung cancer,with the goal of identifying effective indicators for early diagnosis and treatment. Methods:A total of 234 hospitalized lung cancer patients at Hebei General Hospital were enrolled as the lung cancer group,71 patients with benign lung diseases as the benign group,and 101 healthy individuals as the healthy group.Serum levels of HE4 and the 5 tumor markers among the 3 groups and analyzed based on pathological type and cancer stage.Logistic regression was used for univariate and multivariate analyses of correlations between HE4 and other clinical parameters. Results:Serum levels of HE4 and the other 5 tumor markers were significantly higher in the lung cancer group compared to the benign and healthy groups(all P<0.05).HE4 was highly expressed in adenocarcinoma;CYFRA21-1 and SCCA were elevated in squamous cell carcinoma;NSE and ProGRP were elevated in small cell lung cancer(P<0.05).Levels of HE4 and the other 5 markers were significantly higher in stage III-IV lung cancer compared to stages I-II lung cancer(P<0.05),with an increasing trend in marker levels correlating with cancer progression(P<0.05).Serum HE4 levels in stage I lung cancer were significantly higher than in the benign and healthy groups(P<0.05),while no statistically significant differences were observed for the other 5 markers among the 3 groups(P>0.05).HE4 levels were positively correlated with pathological type,tumor stage,and other tumor markers(all P<0.05),showing a stronger correlation with tumor stage and CEA(r>0.5).The area under the receiver operator characteristic(ROC)curve for HE4 was the largest;at a cutoff of 80.48 pmol/L,sensitivity was 70.5%and specificity was 91.8%. Conclusion:Serum HE4 plays a valuable role in the diagnosis of lung cancer and,when combined with guideline-recommended tumor markers such as CEA and NSE,can be widely applied in the diagnosis and treatment of lung cancer.关键词
人附睾蛋白4/癌胚抗原/细胞角蛋白19片段/胃泌素释放肽前体/肺癌Key words
human epididymis protein 4/carcinoembryonic antigen/cytokeratin 19 fragment/progastrin-releasing peptide/lung cancer引用本文复制引用
杨雅静,霍丽静..血清HE4联合其他肿瘤标志物在肺癌中的临床应用[J].临床与病理杂志,2025,45(2):149-156,8.基金项目
河北省医学科学研究课题计划项目(20230269).This work was supported by the Medical Science Research Plan Program of Hebei Province,China(20230269). （20230269）
